Noticias y Actividades de Tonix Pharmaceuticals
Presencia
Sede: Estados Unidos
Tonix Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización TNXP (US).
Ejecutivos
Ver el organigrama con sus 31 ejecutivos principales
Biografías más buscadas en Tonix Pharmaceuticals
- Seth Lederman, Co-Founder, Chairman and Chief Executive Officer
- Carolyn Taylor, Director
- Adeoye Olukotun, Director
Recientes movimientos de ejecutivos en Tonix Pharmaceuticals
- Irina Ishak, se ha incorporado a la empresa como General Counsel (noticia publicada el 10 de diciembre de 2025).
- Ganesh Kamath, se ha incorporado a la empresa como Head, Market Access (noticia publicada el 1 de octubre de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en Tonix Pharmaceuticals.
Farmacia
Tonix Pharmaceuticals tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).
Popular M&A news in Farmacia
- Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
- Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).
- Apotex ha presentado su expediente de OPI. Su símbolo de cotización será TSX. (publicado el 2 de junio de 2026).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Tonix Pharmaceuticals
- Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
- Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
- Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
- Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
- Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at
- Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
- View more press releases Close
Redes sociales sobre Tonix Pharmaceuticals
- Tonix Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Tonix Pharmaceuticals en LinkedIn, Twitter y YouTube
